aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
December 15, 2022 08:00 ET
|
aTyr Pharma, Inc.
LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE...
Physicians for Informed Consent Sues State of California, Argues That Doctor Censorship Bill AB 2098 Violates the U.S. Constitution
December 07, 2022 19:50 ET
|
Physicians for Informed Consent
NEWPORT BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent (PIC), an educational nonprofit organization focused on science and statistics, has filed a First Amendment...
Crawford Thomas Recruiting Named to Inc.’s Power Partner Awards
November 16, 2022 11:28 ET
|
Crawford Thomas Recruiting
ORLANDO, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Crawford Thomas Recruiting, the leading nationwide recruiting and staffing firm, announced it has been honored in Inc. Business Media’s inaugural...
Life Reinsurance Market Size In 2022 (New Report) | No. of pages: 115|: Manufacturers Data, Opportunity, Import Export Scenario, Application, Type, Regions and Future Forecast till 2028 with Top Growth Companies
November 16, 2022 02:12 ET
|
Proficient Market Insights
Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Life Reinsurance Market" research report focus on overall information that can help to take decisions on current market situation. Reinsurance, also known as...
aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update
November 10, 2022 16:00 ET
|
aTyr Pharma, Inc.
First patient dosed in Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis; multiple centers in the U.S. are open for enrollment. Company to prioritize resources towards largest value...
aTyr Pharma to Present at Upcoming Investor Conferences
November 10, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
November 09, 2022 08:00 ET
|
aTyr Pharma, Inc.
First therapy in sarcoidosis to reduce steroid burden while demonstrating improvements in key physiologic and quality of life measures. Global pivotal Phase 3 EFZO-FIT™ study currently enrolling. ...
Leading PR and Marketing Agency ÜberStrategist Receives Inc.’s Inaugural Power Partner Award - Celebrating Companies That Help Clients Win
November 01, 2022 07:00 ET
|
UberStrategist
ÜberStrategist Joins 252 Top Firms that Support Nation’s Entrepreneurs and Start-Ups, Based on Measurable Commitment, Reliability, Trust, Creativity, Supportiveness, and Key Virtues that Offer Value...
aTyr Pharma to Present at the Jefferies London Healthcare Conference
October 25, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 25, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets
October 11, 2022 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines...